术前FDG PET/CT体积代谢参数预测非小细胞肺癌淋巴血管侵犯的价值
回顾性纳入161例手术证实的NSCLC患者,评估术前FDG PET/CT体积代谢参数与临床病理因素预测原发肿瘤LVI的效用。LVI组SUVmax、SUVmean、MTV及TLG均显著高于无LVI组,MTV是LVI的独立预测因子,联合N分期和T分期后AUC达0.854。
要点
- MTV≥6.4 cm³是LVI的独立预测因子,敏感度92.1%但特异度仅56.1%。
- MTV联合N1/N2及T2分期预测LVI的AUC可达0.854。
- LVI组体积代谢参数(MTV、TLG)中位数显著高于无LVI组。
关键影像表现/征象
- LVI组SUVmax为15.4±5.9,无LVI组为11.7±7.5(p=.006)。
- LVI组SUVmean为6.0±1.6,无LVI组为5.1±2.0(p=.009)。
- LVI组MTV中位数为15.8 cm³,无LVI组为5.5 cm³(p<.001)。
- LVI组TLG中位数为88.8,无LVI组为24.5(p<.001)。
诊断标准与关键数值
- MTV预测LVI的AUC为0.704,最佳截断值6.4 cm³,敏感度92.1%(35/38),特异度56.1%(69/123),PPV 39.3%(35/89),NPV 95.8%(69/72)。
- 多因素logistic回归中LVI独立预测因子包括MTV≥6.4 cm³(OR=6.5)、N1期(OR=6.4)、N2期(OR=4.0)及T2期(OR=3.6)。
- 上述因素联合预测LVI的AUC为0.854。
- 观察者间一致性ICC:SUVmax'为1.000,SUVmean'为0.997,MTV为0.999。
临床应用与阅片要点
- 术前PET/CT报告中可关注MTV值,MTV≥6.4 cm³提示LVI风险增高。
- MTV联合N分期和T分期可提升LVI预测效能,高NPV有助于排除LVI。
- MTV特异度较低,阳性结果需结合其他临床病理因素综合判断。
局限性
- 回顾性单中心研究,样本量161例。
- 原文指出需进一步研究评估术前FDG PET/CT预测LVI对临床决策的潜在作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Lymphovascular invasion (LVI) is an adverse prognostic indicator in non-small cell lung cancer (NSCLC) and serves as an indication for postoperative adjuvant chemotherapy recommendation after resection. OBJECTIVE. The purpose of this article was to assess the utility of clinicopathologic factors and volumetric metabolic parameters from preoperative FDG PET/CT in predicting primary tumor LVI in NSCLC. METHODS. This retrospective study included 161 patients (mean age, 61.8 ± 8.1 [SD] years; 111 men, 50 women) with surgically confirmed NSCLC who underwent preoperative FDG PET/CT between January 2018 and November 2020. Two nuclear medicine physicians used software to place automated volumes of interest delineating each tumor to record metabolic indexes (SUVmax', SUVmean', and metabolic tumor volume [MTV]), which in turn were used to calculate total lesion glycolysis (TLG). Measurements were first performed independently to determine interobserver agreement using intraclass correlation coefficients (ICCs) and then repeated in consensus. Associations of clinicopathologic and metabolic parameters with tumor LVI status were assessed using t test, Mann-Whitney U test, and chi-square test. Diagnostic performance was assessed using ROC analysis. Multivariable logistic regression analysis was performed to identify independent predictors of tumor LVI. RESULTS. A total of 23.6% (38/161) of patients had LVI. The ICCs were 1.000 for SUVmax', 0.997 for SUVmean', and 0.999 for MTV. Tumors with LVI, compared with tumors without LVI, exhibited higher SUVmax (15.4 ± 5.9 vs 11.7 ± 7.5; p = .006), SUVmean (6.0 ± 1.6 vs 5.1 ± 2.0; p = .009), MTV (median, 15.8 cm3 vs 5.5 cm3; p < .001), and TLG (median, 88.8 vs 24.5; p < .001). Among the metabolic parameters, AUC was highest for MTV (0.704), with an optimal MTV cutoff of 6.4 cm3 yielding sensitivity of 92.1% (35/38), specificity of 56.1% (69/123), PPV of 39.3% (35/89), and NPV of 95.8% (69/72) for LVI. Independent predictors (p < .05) of LVI were MTV (≥ 6.4 cm3; odds ratio [OR], 6.5), category N1 (OR, 6.4) or N2 (OR, 4.0) disease, and category T2 disease (OR, 3.6). These factors combined achieved AUC of 0.854 for LVI. CONCLUSION. The volumetric metabolic parameter MTV from preoperative FDG PET/CT is an independent predictor of tumor LVI in NSCLC. CLINICAL IMPACT. Further studies are warranted to assess the potential role of preoperative prediction of LVI using FDG PET/CT to help guide clinical decision making in NSCLC.
引用
- Li C, Tian Y, Shen Y, et al. Utility of Volumetric Metabolic Parameters on Preoperative FDG PET/CT for Predicting Tumor Lymphovascular Invasion in Non-Small Cell Lung Cancer. AJR Am J Roentgenol. 2021. PMID: 33978465. doi:10.2214/AJR.21.25814
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。